H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

As of market close on Friday, Jan. 24, Moderna stock is up 21.6% this week. Here's why.

We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025. In this article, we are going to ...

Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, personal finance education, top-rated podcasts, and ...

Adar Poonawalla, CEO, Serum Institute of India talks to Arijit Barman about a range of issues including the impact of Trump’s ...

Investing in under-the-radar stocks can be a savvy move for those looking to diversify their portfolios and potentially reap significant rewards. […] The first human bird flu death in the US has ...